Pressroom
Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of R&D
Accomplished scientist and former Biogen EVP brings two decades of R&D leadership, drug development, and venture capital experience to lead scientific and clinical strategy
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
Company advances molecule from deal close to Phase 1 five months after in-licensing the asset
Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH
The acquisition adds a differentiated, oral, IND-stage asset with multi-indication potential to Formation Bio's rapidly growing portfolio.
Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
Formation Bio has acquired worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The acquisition adds a highly differentiated clinical stage asset to Formation Bio's rapidly expanding portfolio of immunology programs.
Formation Bio Expands Leadership Team to Accelerate AI-Driven Drug Development
Former Pfizer, BenevolentAI, Incyte, and AMAG executives join to strengthen clinical, technology, financial, and scientific leadership as company scales its AI-native pharma model
Welcoming Our First Class of Entrepreneurs in Residence
Four Veteran Dealmakers Join Formation Bio to Drive Pipeline Growth and Partnerships
Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio
Mikael Dolsten, MD, PhD, former Chief Scientific Officer and President, Pfizer Research & Development will serve as Formation Bio's Chair of the Drug Picking Committee, Co-Chair of the Investment Advisory Committee, and Chair of Science, Technology, and Product Planning Committee
Introducing Muse
Formation Bio collaborates with Sanofi and OpenAI to Introduce Muse, a first of its kind AI tool to accelerate patient recruitment in drug development.